$1.9 billion transaction is another boost for non-core IP deal-making in pharma
Sierra Oncology buyout is motivated by previously unwanted drug asset it bought for a $3 million upfront fee
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.